The New York Times
An experimental drug is showing what some experts say is intriguing
effectiveness in treating a major cause of death and disability for men
with — that have spread to the bone.
The results of early testing of the drug, to be presented at a
conference in Berlin on Thursday, would be another piece of good news
this week for men with the disease. On Wednesday, a federal advisory
committee said there was adequate evidence that the already marketed
prostate cancer drug Provenge, developed by Dendreon, prolongs lives... Read More
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
